FDA approves Oxervate, the first drug to treat neurotrophic keratitis

The FDA has approved Oxervate for treatment of neurotrophic keratitis, a progressive disease affecting the cornea in fewer than five in 10,000 people, according to an Agency press release.
Oxervate (cenegermin), developed by Dompé farmaceutici SpA, is the first FDA approved drug for the rare disease, which can cause loss of corneal sensation and impair corneal health. Patients with neurotrophic keratitis can experience corneal thinning, ulceration, and perforation in severe cases.
Neurotrophic keratitis has been a “very frustrating disease for physicians,” Flavio Mantelli,

Full Story →